Institutions Conduct Intensive Research as the Brain-Computer Interface Sector heats up

Data shows that as of February 26, when the reporter published this article, a total of 80 listed pharmaceutical and biotech companies have been surveyed by institutions this year. Notably, brain-computer interface concept stocks such as Xiangyu Medical, Aipeng Medical, and Meihui Medical have attracted multiple institutional surveys. The focus of attention includes the progress of brain-computer interface product research and development, commercialization status, and future development plans. Meanwhile, the enthusiasm for innovative drugs going global remains high, with many pharmaceutical companies also receiving institutional attention. Industry insiders say that under the wave of AI technology, the pharmaceutical industry is expected to unlock new growth logic. They remain optimistic about the main theme of pharmaceutical technology driven by innovation, with key focus on brain-computer interfaces, AI medical care, and the international expansion of innovative drugs. (Securities Times)